mobile-banner

2 therapies under 1 co-pay and 1 prior authorization

Simplify access for your patients

Combining the precision of PARP inhibition with abiraterone acetate, AKEEGA® is available as dual action tablets delivered under1*:

Checkmark icon

1 CO-PAY

Checkmark icon

1 PRIOR AUTHORIZATION

*The recommended AKEEGA® dose is 200 mg niraparib/1,000 mg abiraterone acetate (2 tablets, once daily). AKEEGA® is indicated with 10 mg prednisone daily for patients with mCRPC and 5 mg prednisone daily for patients with mCSPC.1

RESOURCES FOR YOUR PRACTICE

Access helpful resources and tools for you and your practice

Coding and access guide

Coding and Access Guide

An informative resource to help you get your patients access to AKEEGA®

National Society of Genetic Counselors logo

Genetic Counseling

A directory of National Society of Genetic Counselors members for genetic testing referrals

Pharmacy benefit investigation form

Patient Enrollment Form

Determine if AKEEGA® is covered by the patient’s insurance plan, including requirements for coverage or prior authorization, any out-of-pocket costs, and approved pharmacies.

Coding and access guide

NDC Flashcard

A quick guide to ordering and storing AKEEGA®

Coding and access guide

Prior Authorization Checklist

A checklist for completing the prior authorization process to avoid fulfillment delays

Coding and access guide

Sample Letter of Medical Necessity

A sample letter to use for guidance when requesting authorization

Coding and access guide

Access Resource Leave Behind

A list of AKEEGA® distributors with contact information

Coding and access guide

Patient OOP Flashcard for Pharmacy Team

An educational flashcard to be shared with pharmacists to help inform them of the IRA-related Medicare patient OOP cost changes in 2026

J&J withMe

Once you have made the clinical decision to prescribe AKEEGA®, Johnson & Johnson has resources to help you support your patients

Comprehensive support throughout your patients treatment journey

At Johnson & Johnson, we are committed to helping people in their fight against cancer. J&J withMe is your single source for access, affordability, and treatment support programs from Johnson & Johnson. Your patients will be connected to AKEEGA withMe.

For Your Office

J&J withMe provides your office with educational support to help patients throughout their treatment journey on AKEEGA®.

Access and Affordability Support:

  • Benefits investigation support
  • Prior authorization support and status monitoring
  • Information on the exceptions and appeals process
  • Coding and billing information
  • Finding cost support options for eligible patients

For Your Patients

Your patients will be connected with AKEEGA withMe, the program that aligns with the J&J medicine they have been prescribed. Support includes:

  • Cost support: J&J withMe Savings Program and other resources
  • Resources and community connections

Get Started With J&J withMe

  • Visit Portal.JNJwithMe.com to investigate insurance coverage for your patients, enroll your patients in savings
  • Visit JNJwithMe.com/hcp/ for access and affordability information for the J&J medicine you prescribed
  • Bookmark these links for quick and easy access!
  • Questions? Call 833-565-9631, Monday through Friday, 8:00 AM to 8:00 PM ET

Get your patient connected to J&J withMe support by asking them to enroll at AKEEGAwithMe.com.

The patient support and resources provided by J&J withMe are not intended to give medical advice, replace a treatment plan from the patient’s healthcare provider, offer services that would normally be performed by the provider’s office, or serve as a reason to prescribe AKEEGA®.

RESOURCES FOR YOUR PATIENTS

Discover resources that can help your patients

Savings program flashcard J&J

J&J withMe Savings Program

Provide your patients with information about potential cost savings for AKEEGA®

Patient welcome brochure

Patient OOP Flashcard Open Enrollment

An educational leave-behind on the IRA-related Medicare patient OOP cost changes in 2026

BRCAm, BRCA gene-mutated; mCRPC, metastatic castration-resistant prostate cancer; mCSPC, metastatic castration-sensitive prostate cancer; NDC, National Drug Code; OOP, out-of-pocket; PARP, poly (ADP-ribose) polymerase.

Reference:

  1. AKEEGA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.